Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021:1342:431-447.
doi: 10.1007/978-3-030-79308-1_19.

Cancer Imaging in Immunotherapy

Murat Ak  1   2 , Yousra Eleneen  1   2 , Mira Ayoub  1   2 , Rivka R Colen  3   4
Affiliations
Review

Cancer Imaging in Immunotherapy

Murat Ak et al. Adv Exp Med Biol. 2021.

Abstract

Immune therapeutics are revolutionizing cancer treatments. In tandem, new and confounding imaging characteristics have appeared that are distinct from those typically seen with conventional cytotoxic therapies. In fact, only 10% of patients on immunotherapy may show tumor shrinkage, typical of positive responses on conventional therapy. Conversely, those on immune therapies may initially demonstrate a delayed response, transient enlargement followed by tumor shrinkage, stable size, or the appearance of new lesions. Response Evaluation Criteria in Solid Tumors (RECIST) or WHO criteria, developed to identify early effects of cytotoxic agents, may not provide a complete evaluation of new emerging treatment response pattern of immunotherapeutic agents. Therefore, new imaging response criteria, such as the immune-related Response Evaluation Criteria in Solid Tumors (irRECIST), immune Response Evaluation Criteria in Solid Tumors (iRECIST), and immune-related Response Criteria (irRC), are proposed. However, FDA approval of emerging therapies including immunotherapies still relies on the current RECIST criteria. In this chapter, we review the traditional and new imaging response criteria for evaluation of solid tumors and briefly touch on some of the more commonly associated immunotherapy-induced adverse events.

Keywords: Imaging; Immunotherapy; Responses criteria.

PubMed Disclaimer

References

    1. Kwak, J. J., et al. (2015). Cancer immunotherapy: Imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics, 35(2), 424–437. - DOI
    1. Nishino, M., et al. (2015). Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. European Journal of Radiology, 84(7), 1259–1268. - DOI
    1. Okada, H., et al. (2015). Immunotherapy response assessment in neuro-oncology: A report of the RANO working group. The Lancet Oncology, 16(15), e534–e542. - DOI
    1. Wolchok, J. D., et al. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clinical Cancer Research, 15(23), 7412–7420. - DOI
    1. Tirkes, T., et al. (2013). Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics, 33(5), 1323–1341. - DOI

Substances

LinkOut - more resources